Details of Drug-Drug Interaction
| Drug General Information (ID: DDI5LNJ03M) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Sulindac | Drug Info | Drospirenone | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antiinflammatory Agents | Contraceptive Agents | |||||||
| Structure | |||||||||
| Mechanism of Sulindac-Drospirenone Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of hyperkalemia Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Sulindac | Drospirenone | |||||||
| Mechanism | Hyperkalemia | Hyperkalemia | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Hyperkalemia | ||||||||
| Factor Description | Hyperkalemia is a condition in which the level of potassium in the blood is higher than normal. While mild cases may not produce symptoms, severe hyperkalemia can lead to fatal arrhythmias if left untreated. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat. | ||||||||